Risk of Hospitalization for Cardiovascular Events with β-Blockers in Hypertensive Patients: A Retrospective Cohort Study.

ABSTRACT:

Introduction

β-Blockers are a heterogenous class of drugs that are no longer recommended for initial antihypertension monotherapy due to unfavorable long-term cardiovascular events observed with non-vasodilatory β-blockers. However, the comparative cardiovascular event risk between the vasodilatory β₁-selective antagonist/β₃ agonist nebivolol and non-vasodilatory β₁-blockers, atenolol and metoprolol, is unknown.

Methods

Incident nebivolol, atenolol, or metoprolol monotherapy users with hypertension were identified using US claims data (2007-2014). The first β-blocker claim on/after 1/1/2008 defined the index drug/date. Hypertensive patients without pre-index cardiovascular history were followed until index drug discontinuation (> 90 day suppl

SUBMITTER: Basile J 

PROVIDER: S-EPMC6251822 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature